PD Dr. Sacha Rothschild, USB, Basel
Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979):
Prof. Jean Bourhis, CHUV
Interview about the data of Noronha et al. presented at ASCO “Phase III randomized trial comparing weekly versus 3-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer”.
Prof. Marco Merlano, Italy
Explains the ADCC mechanism, why this mechanism is important regarding cetuximab and the greatest potential for EGFR antibodies in head and neck tumors: